Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection.
Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection.
复制标题
DOI：
10.1186/1743-422x-3-56
复制
发表时间：
2006-07-19
期刊：
影响因子：
4.8
通讯作者：
Polyak SJ
中科院分区：
文献类型：
--
作者：
Boriskin YS;Pécheur EI;Polyak SJ
阿比朵尔（ARB）是一种抗病毒化合物，最初被证明对治疗流感和其他几种呼吸道病毒感染有效。ARB的广谱抗病毒活性使我们评估了其对细胞培养物中丙型肝炎病毒（HCV）感染和复制的影响。长期ARB治疗慢性复制基因组长度基因型1b复制子的Huh 7细胞导致病毒RNA和蛋白质表达的持续减少，并最终治愈HCV感染的细胞。用15 μM ARB预处理人肝癌Huh 7.5.1细胞24至48小时，可抑制JFH-1病毒的急性感染高达1000倍。ARB对HCV的抑制作用不是由于广义的细胞毒性，也不是由于IFN抗病毒信号通路的增强，而是涉及受损的病毒介导的膜融合。ARB对膜的亲和力可能会抑制HCV生命周期中依赖于膜的几个方面。
Arbidol (ARB) is an antiviral compound that was originally proven effective for treatment of influenza and several other respiratory viral infections. The broad spectrum of ARB anti-viral activity led us to evaluate its effect on hepatitis C virus (HCV) infection and replication in cell culture. Long-term ARB treatment of Huh7 cells chronically replicating a genomic length genotype 1b replicon resulted in sustained reduction of viral RNA and protein expression, and eventually cured HCV infected cells. Pre-treatment of human hepatoma Huh7.5.1 cells with 15 μM ARB for 24 to 48 hours inhibited acute infection with JFH-1 virus by up to 1000-fold. The inhibitory effect of ARB on HCV was not due to generalized cytotoxicity, nor to augmentation of IFN antiviral signaling pathways, but involved impaired virus-mediated membrane fusion. ARB's affinity for membranes may inhibit several aspects of the HCV lifecycle that are membrane-dependent.